Optimizing sodium-glucose co-transporter 2 inhibitor use in patients with heart failure with reduced ejection fraction: A collaborative clinical practice statement

Warden, Bruce A.; Steiner, Julia; Camacho, Albert; Nguyen, Khanh Ngoc; Purnell, Jonathan Q.; Duell, P. Barton; Craigan, Courtney; Osborn, Diane; Fazio, Sergio

doi:10.1016/j.ajpc.2021.100183

Cited by 4 publications

(2 citation statements)

References 85 publications

(143 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinical pharmacists have been identified as being in position to improve prescribing of DM medications with cardiovascular benefits. 29,30 Additionally, clinical pharmacists have been shown to positively impact the prescribing of beneficial DM medications by PCP. 31…”

Section: Introductionmentioning

confidence: 99%

Clinical Pharmacy Specialist Collaborative Management and Prescription of Diabetes Medications with Cardiovascular Benefit

Ballister

Hernandez

Quffa

et al. 2022

Journal of Pharmacy Practice

View full text Add to dashboard Cite

Background Involvement of Clinical Pharmacy Specialists (CPS) in the care of patients with diabetes mellitus (DM) has been demonstrated to be beneficial. Whether this positive impact applies to increased use of cardiovascular risk-reducing medications is less well established. Objective To determine the association of CPS co-management on the prescription of diabetes medications with proven cardiovascular benefits for patients with DM and established cardiovascular disease in the primary care setting. Methods This retrospective cohort study evaluated patients in a Veterans Affairs health-system in primary care settings from February 1, 2019, through January 31, 2020. Patients were included if they had type 2 DM treated with at least one medication and had CVD. Patients were grouped into two cohorts for comparison, those with CPS co-management and those without. The primary outcome was the proportion of patients in each group with new prescriptions for empagliflozin or liraglutide initiated during the study timeframe. Results In total, 8058 patients were found eligible for inclusion in the study. Clinical co-management by a CPS was provided to 2099 patients. Study medications were prescribed, approved, and initiated in 596 patients during the study period, including 391 (18.6%) in the CPS group and 205 (3.4%) in the non-CPS group (P < .001). Conclusion This study showed CPS involvement is associated with increased prescribing of diabetes medications with proven cardiovascular benefits.

show abstract

Section: Introductionmentioning

confidence: 99%

Clinical Pharmacy Specialist Collaborative Management and Prescription of Diabetes Medications with Cardiovascular Benefit

Ballister

Hernandez

Quffa

et al. 2022

Journal of Pharmacy Practice

View full text Add to dashboard Cite

show abstract

“…[73][74][75][76] Enhancing the knowledge of frontline primary care physicians and patients for cardiorenal benefits of SGLT-2i and risk control, addition of SGLT-2i by policymakers as crucial performance indicator along with glycemic control, adoption of multidisciplinary team-based care strategies, and providing access to financial assistance programs can improve the uptake of SGLT-2i for management of CKD. 37,76,77…”

Section: Dovepressmentioning

confidence: 99%

Impact of Sodium-Glucose Cotransporter-2 Inhibitors in the Management of Chronic Kidney Disease: A Middle East and Africa Perspective

Elkeraie,

Al-Ghamdi,

Abu-Alfa

et al. 2024

IJNRD

View full text Add to dashboard Cite

Chronic kidney disease (CKD) is a major public health concern in the Middle East and Africa (MEA) region and a leading cause of death in patients with type 2 diabetes mellitus (T2DM) and hypertension. Early initiation of sodium-glucose cotransporter - 2 inhibitors (SGLT-2i) and proper sequencing with renin-angiotensin-aldosterone system inhibitors (RAASi) in these patients may result in better clinical outcomes due to their cardioprotective properties and complementary mechanisms of action. In this review, we present guideline-based consensus recommendations by experts from the MEA region, as practical algorithms for screening, early detection, nephrology referral, and treatment pathways for CKD management in patients with hypertension and diabetes mellitus. This study will help physicians take timely and appropriate actions to provide better care to patients with CKD or those at high risk of CKD.

show abstract

“Positive Kidney Health”: Implementation and design of a pharmacist-led intervention for patients at risk for development or progression of chronic kidney disease

Vu¹,

Nicholas²,

Waterman³

et al. 2023

Journal of the American Pharmacists Association

View full text Add to dashboard Cite

Optimizing sodium-glucose co-transporter 2 inhibitor use in patients with heart failure with reduced ejection fraction: A collaborative clinical practice statement

Cited by 4 publications

References 85 publications

Clinical Pharmacy Specialist Collaborative Management and Prescription of Diabetes Medications with Cardiovascular Benefit

Clinical Pharmacy Specialist Collaborative Management and Prescription of Diabetes Medications with Cardiovascular Benefit

Impact of Sodium-Glucose Cotransporter-2 Inhibitors in the Management of Chronic Kidney Disease: A Middle East and Africa Perspective

“Positive Kidney Health”: Implementation and design of a pharmacist-led intervention for patients at risk for development or progression of chronic kidney disease

Contact Info

Product

Resources

About